U3 Shut Down As Daiichi Sankyo Streamlines R&D
This article was originally published in PharmAsia News
Some seven and a half years after buying the venture, Daiichi Sankyo is shutting down its German oncology biologics research operation U3 Pharma, although its remaining pipeline assets are being retained internally.
You may also be interested in...
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.